Literature DB >> 8192689

Antiepileptics from gamma-aminobutyric acid.

G Satzinger1.   

Abstract

The importance of GABAergic neurons as the control sites at the central excitation level is generally accepted. Recently, knowledge has expanded concerning the participation of the GABAergic system in the pathophysiology of neurological and psychiatric diseases. Especially the pathogenesis of epilepsy is seen in connection with a loss of neuronal inhibitory function. Investigations into the structure and biochemistry of the central inhibitory transmitter GABA (gamma-aminobutyric acid) and the GABAA receptor resulted in medicinal-chemical strategies to stimulate GABAergic neurotransmission. With the synthesis of the GABA derivatives progabide, vigabatrin and gabapentin, a very promising enrichment of antiepileptic pharmacotherapy has become available.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8192689

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

Review 1.  Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Andrea Diana; Rita Pillai; Paolo Bongioanni; Aidan G O'Keeffe; Robert G Miller; Dan H Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-01-09

2.  Unbiased membrane permeability parameters for gabapentin using boundary layer approach.

Authors:  Jitender Madan; Garima Chawla; Vinod Arora; Rajiv Malik; Arvind K Bansal
Journal:  AAPS J       Date:  2005-09-02       Impact factor: 4.009

3.  An investigation of the anti-inflammatory effects of gabapentin on acetic acid-induced colitis in rats.

Authors:  Azadeh Motavallian; Saba Bouzari; Ehsan Zamani; Paridokht Karimian; Sara Dabirian; Mehdi Molavi; Forough Aghajani Torshkooh
Journal:  Mol Biol Rep       Date:  2021-04-29       Impact factor: 2.316

Review 4.  Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice.

Authors:  S Natsch; Y A Hekster; A Keyser; C L Deckers; H Meinardi; W O Renier
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

5.  Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin.

Authors:  B Brawek; M Löffler; D J Dooley; A Weyerbrock; T J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-12       Impact factor: 3.000

6.  Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice.

Authors:  Mahindra Chincholkar
Journal:  Br J Pain       Date:  2020-03-13

7.  Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis.

Authors:  Kerensa T Houghton; Alexandra Forrest; Amine Awad; Lauren Z Atkinson; Sarah Stockton; Paul J Harrison; John R Geddes; Andrea Cipriani
Journal:  BMJ Open       Date:  2017-03-27       Impact factor: 2.692

8.  Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder.

Authors:  John J Mariani; Martina Pavlicova; Cale Basaraba; Agnieszka Mamczur-Fuller; Daniel J Brooks; Adam Bisaga; Kenneth M Carpenter; Edward V Nunes; Frances R Levin
Journal:  Alcohol Clin Exp Res       Date:  2021-07-05       Impact factor: 3.928

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.